文献速递鼻科

变应性鼻炎患者的嗅觉:MP-AzeFlu 治疗成功的指标

Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy.
PubMed 文献 · Int Forum Allergy Rhinol · 2016-11-26

这项前瞻性多中心观察性研究纳入 47 例持续性变应性鼻炎患者,予 MP-AzeFlu(每鼻孔 1 喷、每日 2 次)治疗 3 个月,用 Sniffin' Sticks 测嗅觉、VAS 记鼻部症状。TDI 评分从基线 23.7 升至 1 个月 34.2 和 3 个月 37.1(均 p < 0.001),VAS 从基线 84.3 降至 1 个月 32.4 和 3 个月 26.2(p < 0.001),变应性鼻炎严重程度与嗅觉功能及 VAS 均存在高度显著交互作用(均 p < 0.001)。

要点

  • MP-AzeFlu 治疗 3 个月与持续性变应性鼻炎患者 TDI 评分显著改善相关。
  • TDI 从基线 23.7 升至 1 个月 34.2 和 3 个月 37.1(均 p < 0.001)。
  • VAS 从基线 84.3 降至 1 个月 32.4 和 3 个月 26.2(p < 0.001)。

核心结论

  • MP-AzeFlu 与持续性变应性鼻炎患者的嗅觉改善相关。
  • 改良 ARIA 严重程度分类是患者嗅觉功能的指标。
  • 嗅觉评估似乎是抗过敏/抗炎治疗临床成功的可靠指标。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入 47 例持续性变应性鼻炎患者。
  • 采用改良 ARIA 标准结合皮肤点刺试验阳性、血清特异性 IgE 及鼻激发反应判定变应性鼻炎病程与严重程度。
  • 患者接受 MP-AzeFlu(每鼻孔 1 喷、每日 2 次)治疗 3 个月,于基线、1 个月和 3 个月用 Sniffin' Sticks 测嗅觉并以 VAS 记录鼻部症状评分。

主要发现

  • TDI 评分从基线 23.7 升至 1 个月 34.2(p < 0.001)和 3 个月 37.1(p < 0.001)。
  • VAS 从基线 84.3 降至 1 个月 32.4 和 3 个月 26.2(p < 0.001)。
  • 变应性鼻炎严重程度与嗅觉功能存在高度显著交互作用(p < 0.001),与 VAS 也存在高度显著交互作用(p < 0.001)。

临床怎么用

  • 作者认为,嗅觉评估似乎是抗过敏/抗炎治疗临床成功的可靠指标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to investigate the effect of MP-AzeFlu on olfaction and the interaction between severity of allergic rhinitis and olfactory improvement after therapy. METHODS: A prospective, multicenter, observational study was performed on 47 patients with persistent allergic rhinitis. Duration and severity of allergic rhinitis was diagnosed and classified using the modified Allergic Rhinitis and its Impact on Asthma (ARIA) criteria and the proof of allergen sensitization from positive skin-prick tests, specific immonoglobulin E (IgE) in serum, and nasal provocation response. Patients were treated with MP-AzeFlu (1 spray/nostril twice daily) over 3 months. Olfactory function was assessed at baseline and at 1 and 3 months of therapy using the "Sniffin' Sticks" test. In addition, a nasal symptom score was recorded on a visual analog scale (VAS) at each given time-point. RESULTS: MP-AzeFlu was found to be associated with a significant improvement in TDI score, from 23.7 at baseline to 34.2 at 1 month (p < 0.001) and 37.1 at 3 months (p < 0.001) of treatment. Furthermore, a highly significant improvement of symptoms over time (p < 0.001; VAS at baseline: 84.3; 1 month: 32.4; 3 months: 26.2) could be demonstrated. Most importantly, there was a highly significant interaction between the severity of allergic rhinitis and olfactory function (p < 0.001) and VAS (p < 0.001). CONCLUSION: MP-AzeFlu is associated with olfactory improvement in persistent allergic rhinitis patients. Further, the modified ARIA severity classification is an indicator of patients' olfactory function. Moreover, assessment of olfaction seems to be a reliable indicator of the clinical success of antiallergic/antiinflammatory therapy.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Klimek L, Poletti SC, Sperl A, et al. Olfaction in patients with allergic rhinitis: an indicator of successful MP-AzeFlu therapy. Int Forum Allergy Rhinol. 2016. PMID: 27888645. doi:10.1002/alr.21877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。